Premium
Plasminogen activators and their inhibitors in leukemic cell homogenates
Author(s) -
Wada Hideo,
Kumeda Yasurou,
Ogasawara Zin,
Ohiwa Michiaki,
Kaneko Toshihiro,
Tamaki Shigehisa,
Ohno Toshiyuki,
Kageyama Sinichi,
Kobayashi Thoru,
Deguchi Katsumi,
Shirakawa Shigeru
Publication year - 1993
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830420205
Subject(s) - cancer research , medicine , chemistry , pharmacology
Plasminogen activator (PA) and PA inhibitor (PAI) were measured in homogenates of leukemia cells. Both PA and PAI levels were higher in non‐lymphoblastic leukemia than in lymphoblastic leukemia. The levels were below the sensitivity of determination in chronic myelocytic leukemia (CML) but showed significant increases in blast crisis (CML, bc). The level of the tissue type PA (t‐PA) antigen was highest in acute myelobtestic leukemia (AML) and that of the urokinase type PA (u‐PA) was highest in acute promyeiocytic leukemia (APL). The PAH antigen showed no marked cell specificity, but the PAI‐II antigen was markedly increased in myelomonocytic leukemia and acute monocytic leukemia (AMoL). From these findings, various PAs and PAIs are considered to be present in leukemia cells and to be involved in hemostatic disorders, thus they are of diagnostic value in leukemia. © 1993 Wiley‐Liss, Inc.